ELAHERE (mirvetuximab soravtansine-gynx)
TherapyAbbVie
ELAHERE (mirvetuximab soravtansine-gynx) from AbbVie is an antibody-drug conjugate used in FRα-positive ovarian cancer.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and ELAHERE. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where ELAHERE is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Solid Tumor · Ovary/Peritoneum | FOLR1
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for ELAHERE.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering ELAHERE for eligible patients.
Test
Ventana FOLR1 (FOLR-2.1) RxDx Assay
Ventana Medical Systems, Inc. (Roche Diagnostics)
Method
IHC
Specimen
Tissue (FFPE)
1 approvalView test profile →